The role of anti-Müllerian hormone in female fertility and infertility - An overview

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 11, 2012, Pages 1252-1260

  Grynnerup, Anna Garcia Alix ^a   Lindhard, Anette ^a   Sørensen, Steen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anti M llerian hormone; granulosa cell tumor; low responder; ovarian hyperstimulation syndrome; ovarian reserve; polycystic ovary syndrome

Indexed keywords

FOLLITROPIN; MUELLERIAN INHIBITING FACTOR;

BODY MASS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GRANULOSA CELL TUMOR; HUMAN; META ANALYSIS; OVARIAN RESERVE; OVARY FOLLICLE; OVARY POLYCYSTIC DISEASE; PREDICTIVE VALUE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUBERTY; REVIEW; SENSITIVITY AND SPECIFICITY; SMOKING; SYSTEMATIC REVIEW;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FERTILITY; FERTILIZATION IN VITRO; HUMANS; INFERTILITY, FEMALE; LIVE BIRTH; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY OUTCOME;

EID: 84863952102     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2012.01471.x     Document Type: Review

References (80)

1. Gougeon A, Ecochard R, Thalabard JC,. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. Biol Reprod. 1994; 50: 653-63.
2. te Velde ER, Pearson PL,. The variability of female reproductive ageing. Hum Reprod Update. 2002; 8: 141-54.
3. Massagué J,. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990; 6: 597-641.
4. Jost A,. Reserches sur la differenciation de l'embryon de lapin. Nat Microsc Morphol Exp. 1947; 36: 271-289.
5. Rajpert-De Meyts E, Jørgensen N, Graem N, Müller J, Cate RL, Skakkebaek NE,. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999; 84: 3836-44.
6. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, Best S, et al,. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab. 1996; 81: 571-6.
7. McGee EA, Hsueh AJ,. Initial and cyclic recruitment of ovarian follicles. Endocr Rev. 2000; 21: 200-14.
8. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al,. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004; 10: 77-83.
9. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, et al,. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology. 1999; 140: 5789-96.
10. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al,. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002; 143: 1076-84.
11. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al,. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001; 142: 4891-9.
12. Fréour T, Mirallié S, Bach-Ngohou K, Denis M, Barrière P, Masson D,. Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta. 2007; 375: 162-4.
13. Bersinger NA, Wunder D, Birkhäuser MH, Guibourdenche J,. Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid. Clin Chim Acta. 2007; 384: 174-5.
14. Kumar A, Kalra B, Patel A, McDavid L, Roudebush WE,. Development of a second generation anti-Müllerian hormone (AMH) ELISA. J Immunol Methods. 2010; 362: 51-9.
15. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF,. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992; 7: 1342-6.
16. Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW, te Velde ER,. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril. 1999; 72: 845-51.
17. Kevenaar ME, Meerasahib MF, Kramer P, van de Lang-Born BM, de Jong FH, Groome NP, et al,. Serum anti-Müllerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology. 2006; 147: 3228-34.
18. Appt SE, Clarkson TB, Chen H, Adams MR, Christian PJ, Hoyer PB, et al,. Serum antimüllerian hormone predicts ovarian reserve in a monkey model. Menopause. 2009; 16: 597-601.
19. Pellestor F, Andréo B, Arnal F, Humeau C, Demaille J,. Maternal aging and chromosomal abnormalities: new data drawn from in vitro unfertilized human oocytes. Hum Genet. 2003; 112: 195-203.
20. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, Themmen AP, et al,. Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online. 2008; 16: 664-70.
21. Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, et al,. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab. 1995; 80: 3537-45.
22. de Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC,. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002; 77: 357-62.
23. La Marca A, Stabile G, Artenisio AC, Volpe A,. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006; 21: 3103-7.
24. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ,. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006; 91: 4057-63.
25. Zec I, TislariáMedenjak D, Bukovec-Megla Z, Harni V, KusiáZ,. Serum levels of antimüllerian hormone in women with regular menstrual cycles. Acta Clin Croat. 2010; 49: 405-9.
26. La Marca A, Giulini S, Orvieto R, De Leo V, Volpe A,. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005; 20: 1569-72.
27. Li HW, Wong CY, Yeung WS, Ho PC, Ng EH,. Serum anti-müllerian hormone level is not altered in women using hormonal contraceptives. Contraception. 2011; 83: 582-5.
28. Mohamed KA, Davies WA, Lashen H,. Antimüllerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril. 2006; 86: 1515-7.
29. Shaw CM, Stanczyk FZ, Egleston BL, Kahle LL, Spittle CS, Godwin AK, et al,. Serum antimüllerian hormone in healthy premenopausal women. Fertil Steril. 2011; 95: 2718-21.
30. Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC,. Changes in anti-Müllerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility. Hum Reprod. 2004; 19: 2036-42.
31. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, et al,. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005; 83: 979-87.
32. Tehrani FR, Solaymani-Dodaran M, Azizi F,. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause. 2009; 16: 797-802.
33. Tehrani FR, Shakeri N, Solaymani-Dodaran M, Azizi F,. Predicting age at menopause from serum antimüllerian hormone concentration. Menopause. 2011; 18: 766-70.
34. Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, et al,. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J Clin Endocrinol Metab. 2011; 96: 2532-9.
35. Fauser BC, Diedrich K, Devroey P,. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008; 14: 1-14.
36. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS,. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol. 2009; 7: 100.
37. Klinkert ER, Broekmans FJ, Looman CW, Te Velde ER,. A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles. Fertil Steril. 2004; 81: 1247-53.
38. Ulug U, Ben-Shlomo I, Turan E, Erden HF, Akman MA, Bahceci M,. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod Biomed Online. 2003; 6: 439-43.
39. Cordes T, Schultze-Mosgau A, Diedrich K, Griesinger G,. Ongoing pregnancy after human menopausal gonadotropin stimulation and timed intercourse in a 40-year-old woman with undetectable antimüllerian hormone levels. Fertil Steril. 2010; 94: e70; author reply e71-2.
40. Weghofer A, Dietrich W, Barad DH, Gleicher N,. Live birth chances in women with extremely low-serum anti-Mullerian hormone levels. Hum Reprod. 2011; 26: 1905-9.
41. Wang JG, Douglas NC, Nakhuda GS, Choi JM, Park SJ, Thornton MH, et al,. The association between anti-Müllerian hormone and IVF pregnancy outcomes is influenced by age. Reprod Biomed Online. 2010; 21: 757-61.
42. Barad DH, Weghofer A, Gleicher N,. Utility of age-specific serum anti-Müllerian hormone concentrations. Reprod Biomed Online. 2011; 22: 284-91.
43. Sun W, Stegmann BJ, Henne M, Catherino WH, Segars JH,. A new approach to ovarian reserve testing. Fertil Steril. 2008; 90: 2196-202.
44. Klinkert ER, Broekmans FJ, Looman CW, Habbema JD, te Velde ER,. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum Reprod. 2005; 20: 611-5.
45. Popovic-Todorovic B, Loft A, Bredkjaeer HE, Bangsbøll S, Nielsen IK, Andersen AN,. A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Hum Reprod. 2003; 18: 2275-82.
46. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al,. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009; 24: 867-75.
47. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008; 90: S188-93.
48. Nelson SM, Yates RW, Fleming R,. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cyclesâimplications for individualization of therapy. Hum Reprod. 2007; 22: 2414-21.
49. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC,. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006; 113: 1210-7.
50. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41-7.
51. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC,. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004; 89: 318-23.
52. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al,. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88: 5957-62.
53. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, et al,. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007; 92: 240-5.
54. Eldar-Geva T, Margalioth EJ, Gal M, Ben-Chetrit A, Algur N, Zylber-Haran E, et al,. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod. 2005; 20: 1814-9.
55. La Marca A, Orvieto R, Giulini S, Jasonni VM, Volpe A, De Leo V,. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril. 2004; 82: 970-2.
56. Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D,. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009; 296: E238-43.
57. Moran LJ, Noakes M, Clifton PM, Norman RJ,. The use of anti-müllerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92: 3796-802.
58. Pigny P, Jonard S, Robert Y, Dewailly D,. Serum anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91: 941-5.
59. van Beek RD, van den Heuvel-Eibrink MM, Laven JS, de Jong FH, Themmen AP, Hakvoort-Cammel FG, et al,. Anti-Müllerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab. 2007; 92: 3869-74.
60. Jamieson S, Fuller PJ,. Molecular pathogenesis of granulosa cell tumors of the ovary. Endocr Rev. 2012; 33: 109-44.
61. La Marca A, Volpe A,. The anti-Mullerian hormone and ovarian cancer. Hum Reprod Update. 2007; 13: 265-73.
62. Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, et al,. Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res. 2006; 12: 1593-8.
63. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P,. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 2005; 112: 1384-90.
64. Tremellen KP, Kolo M, Gilmore A, Lekamge DN,. Anti-müllerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol. 2005; 45: 20-4.
65. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al,. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod. 2007; 22: 766-71.
66. McIlveen M, Skull JD, Ledger WL,. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod. 2007; 22: 778-85.
67. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP,. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online. 2007; 14: 602-10.
68. Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E,. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Human Reprod. 2008; 23: 1359-65.
69. Riggs RM, Duran EH, Baker MW, Kimble TD, Hobeika E, Yin L, et al,. Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B, and age. Am J Obstet Gynecol. 2008; 199: 202.e1-8.
70. Barad DH, Weghofer A, Gleicher N,. Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function. Fertil Steril. 2009; 91: 1553-5.
71. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P, et al,. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril. 2009; 92: 1586-93.
72. Al-Azemi M, Killick SR, Duffy S, Pye C, Refaat B, Hill N, et al,. Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction. Hum Reprod. 2011; 26: 414-22.
73. Elgindy EA, El-Haieg DO, El-Sebaey A,. Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril. 2008; 89: 1670-6.
74. Li HW, Yeung WS, Lau EY, Ho PC, Ng EH,. Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine insemination. Fertil Steril. 2010; 94: 2177-81.
75. Majumder K, Gelbaya TA, Laing I, Nardo LG,. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos. Eur J Obstet Gynecol Reprod Biol. 2010; 150: 166-70.
76. Kini S, Li HW, Morrell D, Pickering S, Thong KJ,. Anti-mullerian hormone and cumulative pregnancy outcome in in-vitro fertilization. J Assist Reprod Genet. 2010; 27: 449-56.
77. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, et al,. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008; 23: 160-7.
78. Aflatoonian A, Oskouian H, Ahmadi S, Oskouian L,. Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm). J Assist Reprod Genet. 2009; 26: 319-25.
79. Honnma H, Baba T, Sasaki M, Hashiba Y, Oguri H, Fukunaga T, et al,. Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization. J Assist Reprod Genet. 2011; 29: 117-25.
80. Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I,. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011; 28: 1197-1203.